Atovaquone is a new broad-spectrum antiprotozoal drug with high in vitro activity against multidrug-resistant \textit{Plasmodium falciparum}. Its specific action against protozoans is based on the inhibition of the parasite cytochrome \textit{bcl} complex of the mitochondrial electron transport system. Protozoans may develop atovaquone resistance by the selection of a mutant cytochrome \textit{b} gene. With the increasing availability of atovaquone-proguanil combination for prophylaxis and treatment of malarial infections, it is necessary to establish baseline data on atovaquone sensitivity before the drug is introduced massively in an endemic region. For this purpose, the activity of atovaquone was assessed indirectly by in vitro drug sensitivity assays with several serum substitutes and DNA sequencing of the cytochrome \textit{b} gene. Using the standard in vitro assay procedures with 10% human serum, the geometric mean 50% inhibitory concentration (IC$_{50}$) for atovaquone was calculated to be 1.15 nM (range = 0.460–4.17 nM), while the use of 10% fetal calf serum resulted in lower IC$_{50}$ (geometric mean = 0.575, range = 0.266–2.20 nM). The use of Albumax, a lipid-enriched bovine albumin, among the same concentration range (0.25–16 nM) showed poor results. None of the 37 isolates with an atovaquone IC$_{50} < 4.17$ nM displayed any mutation. Further monitoring of atovaquone-resistant \textit{P. falciparum} is warranted for the rational use of this new antimalarial drug.

\textbf{INTRODUCTION}

Atovaquone, a naphthoquinone derivative, is a new antimalarial drug with high activity against multidrug-resistant \textit{Plasmodium falciparum}, as well as against other protozoans. It is one of the rare compounds belonging to an entirely new chemical class that attained clinical phase of development. In vitro studies on clinical isolates of \textit{P. falciparum} from different geographic origins have shown its high activity. Preliminary clinical studies on atovaquone administered as monotherapy have shown its rapid action to clear parasitemia, but a high recrudescence rate of 33% was observed in a study in Thailand. These recrudescent parasites were highly resistant in vitro to atovaquone, with an approximately 1,000-fold increase in inhibitory concentrations. Additional in vitro studies have identified doxycycline and proguanil (biguanide), but not its non-biguanide metabolite cycloguanil or pyrimethamine (non-biguanide dihydrofolate reductase inhibitor), as synergistic partners of atovaquone. Clinical studies confirmed the \textit{in vitro} results with high cure rates for atovaquone-proguanil and atovaquone-doxycycline combinations, but not atovaquone-pyrimethamine. Further clinical studies on the atovaquone-proguanil combination conducted in different parts of the world have largely confirmed its efficacy, tolerance, and safety for both treatment and prophylaxis. At the present time, the atovaquone-proguanil combination is available in many non-endemic countries for prophylaxis of travelers visiting endemic areas for up to one month, and in some endemic countries, the drug combination was available until recently for the treatment of multidrug-resistant \textit{P. falciparum} infections through the drug donation program. The mechanism of action of atovaquone is based on the selective inhibition of the cytochrome \textit{bcl} complex of the mitochondrial electron transport system in malaria parasites. Proguanil itself does not have any effect on mitochondrial functions, and its weak inhibitory action (nor the strong inhibitory action of cycloguanil and pyrimethamine) on dihydrofolate reductase does not seem to be involved in the synergistic interaction with atovaquone. One recent study has suggested that proguanil may enhance the ability of atovaquone to perturb mitochondrial membrane potential at lower doses, but the exact mechanism of synergy between these two drugs is not known. Atovaquone resistance has been associated with the capacity of malaria parasites to maintain normal functions of the mitochondrial electron transport despite the presence of high drug concentrations. The underlying genetic basis for atovaquone resistance has linked to the presence of specific mutations in the cytochrome \textit{b} gene in both rodent malaria parasites and laboratory-adapted strains of \textit{P. falciparum}.

In the African continent, up to one million doses of the atovaquone-proguanil combination had been available annually for the treatment of uncomplicated \textit{P. falciparum} infections in some countries through the drug donation program in recent years. Although Cameroon was not one of the beneficiary countries until the present time, the massive introduction of the drug combination and its expected uncontrolled distribution in Africa would require close monitoring of drug efficacy. With this perspective in mind, the present study was undertaken to establish the baseline level of \textit{in vitro} atovaquone activity against Cameroonian clinical isolates, analyze the cytochrome \textit{b} gene sequence, and assess the potential of fresh clinical isolates to develop atovaquone resistance.

\textbf{MATERIALS AND METHODS}

\textbf{Parasites.} Venous blood samples were obtained after informed consent was obtained from children ≥12 years old and adults spontaneously consulting the Nlongkak Catholic Missionary Dispensary in Yaounde, Cameroon in 2001–2002 if the following criteria were met: signs and symptoms of acute uncomplicated malaria, the presence of \textit{P. falciparum} at a parasitemia ≥0.1% without other \textit{Plasmodium} species, and a negative Saker-Solomons urine test result for 4-aminoquinolines. Young children (<12 years old), pregnant women, anemic patients (hematocrit <20%), and patients with signs and symptoms of severe and complicated malaria
were excluded. The patients were treated with oral amodiaquine, the first-line drug in Cameroon, and followed-up by the dispensary staff to ensure parasite and fever clearance on or before day 4. This study was reviewed and approved by the Cameroon National Ethics Committee and Cameroon National Ministry of Public Health.

**In vitro drug sensitivity assays.** Atovaquone hydrochloride was kindly provided by GlaxoWellcome (Stevenage, Hertfordshire, United Kingdom). A stock solution and two-fold dilutions were prepared in methanol, and 96-well culture plates were pre-coated with dilutions (final concentrations ranging from 0.25 nM to 16 nM) in triplicate and air-dried.

Blood samples were washed three times in RPMI 1640 culture medium within two hours after blood extraction. Infected erythrocytes were suspended in the RPMI 1640 medium containing 25 mM HEPES, 25 mM NaHCO₃, and serum or serum substitute at a hematocrit of 1.5%. One of the following sera or serum substitute was added to supplement the culture medium: 10% non-immune human sera pooled from four European donors, 10% fetal calf serum (tested for mycoplasma) from two different suppliers (batch no. 5-41201; Integro b. v., Amsterdam, The Netherlands and Seromed® batch 8R02; Biochrom KG, Berlin, Germany) or 0.5% Albumax II (Invitrogen Life Technologies, Cergy Pontoise, France). The initial parasitemia was adjusted to 0.6% by adding fresh uninfected erythrocytes if the parasitemia was >1%. The in vitro isotopic microtest was performed as previously described.²⁶ The 50% inhibitory concentration (IC₅₀), defined as the drug concentration corresponding to 50% of the uptake of ³H-hypoxanthine measured in the drug-free control wells, was determined by a non-linear regression analysis using the Prism™ software (GraphPad Software, Inc., San Diego, CA).

**Polymerase chain reaction and sequencing of DNA.** Parasite DNA was extracted from a red blood cell pellet as previously described.²⁶ The *P. falciparum* mitochondrial cytochrome *b* gene was amplified by a nested polymerase chain reaction. The synthetic oligonucleotides were designed from the complete mitochondrial DNA sequence (GenBank accession number M99416).²⁶ In the primary reaction, a 1.1-kilobase pair fragment spanning almost the entire coding region of the cytochrome *b* domain was amplified using the primer pairs PFCYT B-1, 5'-TTAGTTAAAGCACACTTA-3' (forward primer, nucleotides 22–50; nucleotide numbering based on cytochrome *b* domain, the start codon designated as nucleotide 1 in this study corresponds to nucleotide 4758 in M99416) and PFCYT B-2R, 5'-GCTTGGGAGCTGTAATCATAATGTGTTCG-3' (reverse primer, nucleotides 1121–1093). The reaction mixture consisted of genomic DNA, 15 picomole of each primer, buffer (50 mM KCl, 10 mM Tris, pH 8.3), 1.5 mM MgCl₂, 200 μM of deoxynucleoside triphosphates (mixture of dGTP, dATP, dTTP, and dCTP), and one unit of Taq DNA polymerase (Roche Diagnostics, Meylan, France) in a total volume of 50 μL. The PTC-100 thermal cycler (MJ Research, Watertown, MA) was programmed as follows: 94°C for two minutes for the first cycle and 30 seconds in subsequent cycles, 50°C for one minute for the first cycle and 30 seconds in subsequent cycles, and 72°C for one minute in all cycles, for a total of 30 cycles.

A secondary amplification was performed on the primary amplification product with internal primers PFCYT B-3 (forward primer, 5'-ATTTATGATATTTATGTTAACTGC-3', nucleotides 342–365) and PFCYT B-4R (reverse primer, 5'-AGTTGTAAACTCTTGTCTCTGC-3', nucleotides 906–883). Except for the primers and DNA template, the reaction mixture and thermal cycler program for the secondary amplification reaction were identical to that of the primary reaction.

The 565-basepair product was purified using the High Pure PCR Purification kit (Roche Diagnostics). The amplification product was marked with fluorescent nucleotides following the manufacturer's instructions (Perkin Elmer Corp., Les Ulis, France). The ABI Prism automated DNA sequencer (Perkin Elmer Corp.) was used to sequence the extension product.

**Data interpretation.** Parasite growth in drug-free control wells containing RPMI 1640 medium supplemented with different sera or serum substitute in triplicate was expressed as the relative growth index, defined as the percentage of counts per minute (cpm) obtained with Albumax or fetal calf serum, as compared with cpm obtained with 10% human serum. Wild-type and mutant cytochrome *b* alleles were defined on the basis of amino acid sequence differences between TM93-C1088 (a recrudescent isolate obtained from a Thai patient after treatment with atovaquone-pyrimethamine) and other *P. falciparum* clones that have been selected during *in vitro* culture by stepwise exposure to increasing concentration of atovaquone.²³ These parasites display the following amino acid substitutions, singly or in combination: Met133Ile, Tyr268Ser, Lys272Arg, Pro275Thr, Gly280Asp, Ile283Met, and Val284Lys. The DNA sequence of cytochrome *b* gene was compared with the IC₅₀ of atovaquone.

**RESULTS**

The *in vitro* activity of atovaquone was determined in 37 isolates. Among different sera or serum substitute used in this study, 10% fetal calf serum yielded a satisfactory parasite growth in drug-free control wells and consistent parasite growth inhibition at 16 nM, i.e., ≥10-fold difference in the incorporation of tritium-labeled hypoxanthine between drug-free control and the highest drug concentration, allowing an accurate plot of a sigmoid curve by the non-linear regression model. Using 10% fetal calf serum, the geometric mean IC₅₀ for atovaquone was calculated to be 0.575 nM (n = 37, range = 0.266–2.20 nM) (Figure 1). Due to the wide variation in quality and components of animal sera, a second batch of fetal calf serum obtained from another supplier was tested in parallel with the first batch of fetal bovine serum for six isolates. Although the second batch resulted in a better parasite growth in drug-free control wells, with an average growth index of 1.9, similar regression curves and IC₅₀ values were obtained with both batches of fetal calf serum (Table 1).

Using 10% non-immune human serum, interpretable results were obtained for 33 of the 37 isolates. Four assays with human serum were uninterpretable due to inadequate parasite inhibition at 16 nM and/or relatively low hypoxanthine incorporation in the control wells, compared with that obtained at 16 nM. On the average, the atovaquone IC₅₀ was 2.0 times higher with 10% human serum (geometric mean = 1.15 nM, range = 0.460–4.17 nM) than with 10% fetal bovine serum. Although parasite growth varied widely with the two
serum supplements (range of growth index of fetal bovine serum versus human serum/H11505 0.40–2.6) in individual isolates, the mean growth index with fetal bovine serum, compared with that of human serum, was 1.1.

Albumax (0.5%) was used as a serum substitute to determine the atovaquone IC₅₀ for 16 isolates. The growth index of 2.3 was satisfactory, but 8 of 16 assays were uninterpretable due to either non-sigmoidal distribution of experimental points or, more frequently, inadequate parasite growth inhibition at 16 nM. Of eight interpretable assays, only three had similar IC₅₀s as those obtained with fetal calf serum, while the others were between two- and eight-fold higher than the corresponding IC₅₀ obtained with fetal calf serum. Because of these inconsistent results, the use of Albumax as a serum substitute was abandoned after the first 16 assays.

The DNA sequence of cytochrome b was available for all 37 isolates. All sequences were identical at the nucleotide level, with no mutation within the 565-basepair fragment amplified by the polymerase chain reaction, which includes all codons currently known to undergo mutation in P. falciparum. The wild-type cytochrome b gene sequences and low atovaquone IC₅₀s (<4.2 nM using 10% human serum) indicate that all isolates were sensitive to atovaquone.

**DISCUSSION**

Previous in vitro studies have shown the high activity of atovaquone against P. falciparum isolates originating from various African countries and imported into France by returning travelers. Atovaquone IC₅₀s of Cameroonian isolates determined in the present study are within the range of IC₅₀s of isolates originating from various African countries. We have assessed the utility of other serum substitutes for in vitro drug sensitivity assays due to the difficulties in obtaining human sera from non-immune donors. Fetal calf serum seemed to be a suitable substitute, yielding consistent parasite growth and interpretable in vitro assay results for atovaquone. The mean parasite growth was comparable with both sera, and atovaquone IC₅₀ was 2.0 times higher with human serum. Although the reasons for lower atovaquone IC₅₀ with fetal bovine serum were not investigated, it may be conjectured that the differences in the plasma protein composition may favor drug entry into parasites either by the availability of more unbound form of atovaquone or by carrier-mediated processes. In contrast, the use of Albumax resulted in considerably higher atovaquone IC₅₀s, and the concentration range used in this study was probably too low to obtain complete inhibition of parasite growth.

**TABLE 1**

Comparison of fetal calf sera from two different sources for parasite growth and determination of atovaquone IC₅₀.*

<table>
<thead>
<tr>
<th>Isolate</th>
<th>Fetal calf serum 1</th>
<th>Fetal calf serum 2</th>
</tr>
</thead>
<tbody>
<tr>
<td>cpm†</td>
<td>IC₅₀ (nM)</td>
<td>cpm†</td>
</tr>
<tr>
<td>80/01</td>
<td>9,710 ± 898</td>
<td>0.725</td>
</tr>
<tr>
<td>81/01</td>
<td>14,300 ± 1,150</td>
<td>0.579</td>
</tr>
<tr>
<td>82/01</td>
<td>19,210 ± 1,120</td>
<td>1.83</td>
</tr>
<tr>
<td>84/01</td>
<td>7,660 ± 296</td>
<td>0.295</td>
</tr>
<tr>
<td>85/01</td>
<td>9,230 ± 124</td>
<td>0.419</td>
</tr>
<tr>
<td>86/01</td>
<td>4,850 ± 532</td>
<td>0.502</td>
</tr>
</tbody>
</table>

*IC₅₀ = 50% inhibitory concentration.
†Incorporation of ³H-hypoxanthine in drug-free control wells. Results are expressed as the mean ± SD counts per minute (cpm) of three wells.

**FIGURE 1.** Distribution of the atovaquone 50% inhibitory concentration (IC₅₀) for isolates of Plasmodium falciparum in relation to serum supplement. While all 37 isolates had interpretable results with 10% fetal calf serum, 4 of 37 isolates and 8 of 16 isolates had uninterpretable results with 10% human serum and 0.5% Albumax, respectively. The poor results with Albumax led us to abandon further experiments with this serum substitute.
Previous studies have shown that atovaquone-resistant laboratory-adapted parasites can be selected by continuous \textit{in vitro} culture under drug pressure with 10 nM of atovaquone.\textsuperscript{23,27–29} Once acquired, mutations seem to be stable in mutant parasites cultured subsequently without drug pressure. Alignment of cytochrome \(b\) sequences from different organisms and molecular modeling have suggested that only single or double substitutions of amino acid residues at or near the atovaquone binding site within the enzyme may be required to develop atovaquone resistance in protozoans.\textsuperscript{23} In \textit{P. falciparum}, the cytochrome \(b\) gene is highly conserved, with no mutation among 37 isolates. These data, taken together, suggest that at present naturally occurring atovaquone-resistant \textit{P. falciparum} is probably absent in Yaoundé, Cameroon. Further monitoring of atovaquone resistance would be necessary should the drug be introduced in central Africa for either the treatment of \textit{P. falciparum} malaria or prophylaxis/treatment of other protozoan diseases.

Our results show the high \textit{in vitro} activity of atovaquone against Cameroonian isolates and are consistent with those of previous studies on fresh isolates from various African countries.\textsuperscript{2,3} None of the isolates displayed any evidence for atovaquone resistance. Atovaquone \(IC_{50}\) were within a low nanomolar range. Furthermore, the cytochrome \(b\) gene sequence was highly conserved, with no mutation among 37 isolates. These data, taken together, suggest that at present naturally occurring atovaquone-resistant \textit{P. falciparum} is probably absent in Yaoundé, Cameroon. Further monitoring of atovaquone resistance would be necessary should the drug be introduced in central Africa for either the treatment of \textit{P. falciparum} malaria or prophylaxis/treatment of other protozoan diseases.

Received September 7, 2002. Accepted for publication April 26, 2003.

Acknowledgment: I thank Sister Marie-Solange Oko, the personnel of the Nlongkak Catholic Missionary Dispensary, and Delphine Ngo Ndombol for their aid in recruiting patients.

Financial support: This study was supported by the French Ministry of Research (Program VHHPAL/PAL+, Actions 2000 and 2001).

Author’s address: Leonardo K. Basco, Unité de Recherche Paludologie Afro-Tropicale, Institut de Recherche pour le Développement, Laboratoire de Recherche sur le Paludisme, Organisation de Coordonnation pour la Lutte contre les Endémies en Afrique Centrale, BP 288, Yaoundé, Cameroon, Telephone: 237-223-22-32, Fax: 237-223-00-61, E-mail: Leonardo.Basco@ibaic.u-psud.fr or lkbasco@yahoo.fr.

REFERENCES


23. Korsinczky M, Cheng Q, 2000. Mutations in \textit{Plasmodium falciparum} cytochrome \(b\) that are associated with atovaquone resistance are


